77 results about "Low intraocular pressure" patented technology

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a grasping body having a longitudinal axis, and a piercing member coupled to the grasping body, including an elongate body and a beveled piercing tip including a long side and a short side, wherein the piercing member includes a proximal segment, a distal segment, and an aperture nested between the proximal segment and the distal segment, wherein the short side and the aperture are coaxially disposed along a central longitudinal axis of the piercing member, and wherein the piercing member is configured to reciprocate along the longitudinal axis relative to the grasping body.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within Schlemm's canal and that may restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The devices utilize the natural drainage process of the eye and may be implanted with minimal trauma to the eye. Kits may include a support and an introducer for implanting the support within Schlemm's canal. Methods may include implanting a support within Schlemm's canal, where the support is capable of restoring or maintaining at least partial patency of the canal without substantial interference with transmural or transluminal fluid flow across the canal.

The invention discloses an eye implant which comprises an implant body, the implant body is in a strip shape, the outer contour of the upper surface of the implant body is in a protruding arch shape or a semi-arch shape and used for making contact with a sclera, and the lower surface of the implant body is in a plane shape and used for making contact with a choroid; a longitudinal drainage groove is formed in the upper surface of the implant body in the front-back direction of the implant body. The whole implant body is of a structure that the front end and the rear end are gradually thin and the middle is thick or the rear end is gradually thin and the middle is thick to the front end, the implant body can smoothly enter the suprachoroidal space, an originally narrow gap of the suprachoroidal space is expanded, the outflow amount of aqueous humor from the suprachoroidal space is increased through the longitudinal drainage grooves, the drainage effect is good, blocking is not prone to occurring, and the application range is wide. The effect of reducing the intraocular pressure is achieved. The lower surface of the implant body is planar, so that the attachment area of the implant body and the choroid is larger, the implant body can be stably attached to the choroid, the risk of displacement of the anterior chamber and the choroid is reduced, the implant body is prevented from being exposed to the anterior chamber to touch the cornea, and the risk of loss of corneal endothelial cells is reduced to the maximum extent.

Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

The utility model provides a glaucoma drainage device, and relates to the technical field of medical instruments. The glaucoma drainage device comprises a base body, a first hydrophilic layer and a second hydrophilic layer, the base body is provided with a channel penetrating through the base body in the first preset direction. The base body is provided with a first end face and a second end face which are oppositely arranged in the first preset direction. The first hydrophilic layer covers the first end surface and the second end surface; the inner wall of the channel is at least partially covered by the second hydrophilic layer. According to the glaucoma drainage device, accumulation and adhesion of substances such as protein, cells and bacteria in aqueous humor at a channel opening and in a channel can be reduced, the blocking risk of the channel is reduced, the eye aqueous humor can be better led out, intraocular pressure is reduced, and the inflammatory response of eyes can be reduced.

The invention discloses a magnesium alloy composite material and a preparation method and application thereof, and belongs to the technical field of magnesium alloy materials. The magnesium alloy composite material comprises a polymer and a magnesium alloy material, and the mass percentage of the magnesium alloy material in the magnesium alloy composite material does not exceed 50%. The composite material can be obtained by blending a polymer and a magnesium alloy material. The magnesium alloy composite material can be used for preparing devices or medicines for treating eye diseases, and is particularly used for preparing glaucoma drainage implantation instruments. Before magnesium alloy is degraded, the glaucoma drainage implantation instrument containing the magnesium alloy composite material is small in flow capacity, and low intraocular pressure can be prevented; after the magnesium alloy is degraded, a porous structure can be formed, so that the flow capacity of the drainage implantation instrument is increased, a normal drainage effect is achieved, and in addition, the magnesium alloy can also play a role in slowly releasing magnesium ions.

The invention relates to the technical field of medical apparatus and instruments, in particular to an intraoperative viscoelastic agent suction instrument for intraocular lens implantation, which comprises a replacement host, a liquid supply pump, a suction pump and a controller electrically connected with the liquid supply pump and the suction pump, the replacement main machine is further provided with a liquid inlet and a liquid outlet which are communicated with the liquid supply pump, and a suction port and a liquid discharge port which are communicated with the suction pump. An input connector and an output connector are arranged at one end of the handle, a replacement pipe is arranged at the other end of the handle, a liquid adding hole and a suction hole are formed in the free end of the replacement pipe, the liquid adding hole is communicated with the input connector, and the suction hole is communicated with the output connector. By balancing perfusion and suction amounts, intraoperative intraocular pressure fluctuation is avoided, intraoperative intraocular pressure caused by high intraocular pressure or intraocular pressure caused by excessive suction is avoided, and therefore the risk of optic nerve or retina injury is reduced.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral. amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

To provide a composition for lowering an eye pressure in a glaucoma patient.SOLUTION: In one aspect, the present disclosure provides a composition for lowering an eye pressure in a glaucoma patient, containing brimonidine or its pharmaceutically acceptable salt and timolol or its pharmaceutically acceptable salt. The composition of the present disclosure targets a patient of glaucoma. The composition of the present disclosure may be administered to a patient who has been treated with other glaucoma therapeutics but has not shown sufficient treatment effect.SELECTED DRAWING: None

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The invention provides an NO donor type dasatinib derivative as well as a preparation method and application thereof. The derivative is one of a compound 1a-1f and a compound 2a-2f; the derivative has multiple effects of removing senescence cells, reducing intraocular pressure and protecting optic nerves, and is a novel potential treatment medicine for treating glaucoma and senescence-related retinopathy.

A portable, non-invasive eye pressure monitoring device (120) comprising: a battery (106); a microscope (100) that positions the patient's eye to obtain clear scleral images for measuring eye pressure by means of sequential operations; at least one LED light (101) providing uniform illumination for taking scleral images, the intensity of which can be adjusted to avoid glare or shadows caused by uneven illumination; an objective lens (102) that focuses on the sclera by highlighting the blood vessel to ensure a sharp image; an image sensor (103) which receives the light and the magnified image of the objective lens and converts it into a digital format; a processing unit (104) which controls the processes from image acquisition to eye pressure estimation, comprising a pre-processing module (104b), a detection module (104c) and a pressure estimation module (104d), wherein the processing unit (104) finally displays the intraocular pressure to the user based on the vascular pattern via the display device.

The present invention provides a combined ophthalmic pharmaceutical composition of two drugs and a combined composition of three drugs for treating glaucoma and ocular hypertension. The stability of the pharmaceutical composition is greatly improved by salt modification technology. The combined two-drug pharmaceutical composition is produced from netarsudil free base or a pharmaceutically acceptable salt thereof, and an adrenergic β-receptor blocker. The combined three-drug pharmaceutical composition is produced from netarsudil free base or a pharmaceutically acceptable salt thereof, an adrenergic β-receptor blocker, and a prostaglandin analog. The combined pharmaceutical composition of two drugs and three drugs has excellent stability at pH 4.5 to 5.4. By administering an effective amount of the pharmaceutical composition of the present invention once a day to the eyes of patients in need at bedtime or at a time close to bedtime, the intraocular pressure can be effectively and rapidly reduced, and the intraocular pressure can be maintained within the physiological range for a long time. In addition, it has few side effects and high patient compliance.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) to prevent optic nerve damage and restore vision, as well as related compositions and methods.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases that affect optic nerve and retinal ganglion cells. Specifically, the present disclosure provides novel therapeutic antibodies and related compositions and methods that target angiopoietin-associated protein 7 (ANGPTL7) to reduce intraocular pressure (IOP), thereby preventing optic nerve injury and restoring vision.

The invention relates to a method and device for treating eye diseases, and belongs to the field of medical treatment. In order to treat ocular hypertension and glaucoma, a device for reducing intraocular pressure is provided, the device comprising: a plate having a first end and a second end, the plate comprising opposing first and second surfaces wherein the first surface comprises a series of fluid channels, the series of fluid channels are configured in an open cross-network pattern extending from a first end of the plate to a second end of the plate, the width of the first end of the plate being narrower than the width of the second end of the plate to enable the first end of the plate to be inserted into the anterior chamber of the patient, and wherein the second surface comprises a plurality of open cells formed by the fluid channels; a first coating on the first surface, the first coating conforming to a topography of the series of fluid channels, and a second coating on the second surface. The devices described herein can be used to reduce intraocular pressure and treat glaucoma.

The invention relates to the technical field of medical instruments, and provides an integrated ophthalmologic silicone oil extractor which comprises an infusion tube, the infusion tube is a hollow metal tube, the far end of the infusion tube is closed to form a blind end, an infusion opening is formed in the side wall close to the blind end, and the near end of the infusion tube is connected with a connector used for being in butt joint with an infusion apparatus; the silicone oil outflow pipe is a hollow metal pipe and is connected with the infusion pipe side by side, the far end of the silicone oil outflow pipe is a tip, and an inclined plane opening is formed in the tip; the handle is connected with the silicone oil outflow pipe, and a preset included angle is formed between the extending direction of the handle and the axial direction of the silicone oil outflow pipe. The silicone oil extractor provided by the invention can smoothly extract silicone oil through the existing incision of cataract by means of the positive pressure of water. Surgical incisions are few and do not pass through the flat part of the ciliary body, so that bleeding and detachment risks are reduced; the operation can be completed under surface anesthesia, and related hidden dangers of post-bulbous anesthesia are avoided; operation time is short, oil extraction is more thorough, normal intraocular pressure in an operation can be maintained, and complications are reduced.

Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

The utility model discloses an eye pressure detector. The intraocular pressure detection device comprises an intraocular pressure detection structure which is used for obtaining intraocular pressure information due to extrusion after being in contact with the eyes of a user; the information transmission structure is located at one end of the intraocular pressure detection structure, the information transmission structure comprises an information processing module and a displacement measurement structure, the displacement measurement structure comprises a grating strip and a grating sensor, the grating strip is connected with the intraocular pressure detection structure, and the grating sensor is connected with the information processing module. The intraocular pressure detection structure moves to drive the grating strip to move in the sensing area of the grating sensor; the driving unit is located at one end of the information transmission structure and used for controlling the intraocular pressure detection structure to move. According to the intraocular pressure detection device, the positioning unit is arranged, a user can align the probe on the intraocular pressure detection structure with the center position of the eyes of the user through assistance of the positioning unit, the situation that the user deviates when using the intraocular pressure detection device is avoided, and errors of detected data are prevented.

The utility model belongs to the field of medical instruments, and particularly relates to a glaucoma hypertension intraocular pressure drainage device which comprises a tunnel knife used for manufacturing a sclera tunnel and an I-shaped drainage valve used for draining aqueous humor to reduce intraocular pressure, and the tunnel knife comprises a knife head and a knife handle arranged at the tail end of the knife head; a storage groove used for containing the I-shaped drainage valve is formed in the knife handle. A pipe cavity is formed in the I-shaped drainage valve in the length direction of the I-shaped drainage valve and penetrates through the I-shaped drainage valve. The tunnel knife can be used for accurately manufacturing a sclera tunnel with the length of 4mm and the width of 3mm, and the I-shaped drainage valve made of silica gel can be folded and can be implanted into the sclera tunnel through the injector. A tube cavity with the inner diameter being 60 micrometers is formed in the I-shaped drainage valve, aqueous humor can be drained to the position below the conjunctiva through the tube cavity in the drainage valve, intraocular pressure is reduced, damage of intraocular hypertension to eyes is reduced, the I-shaped drainage valve does not need to be fixed through suture, and the drainage device is simple, efficient, accurate and suitable for wide popularization.

Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to the eye. The oligonucleotide compositions contain nucleoside modifications.

The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.

The invention discloses an application of a miR-27a-3p inhibitor in preparation of a medicine for improving glaucoma. Glaucoma is a global main blinding neurodegenerative disease, retinal ganglion cell (RGC) apoptosis is a core pathological feature of the glaucoma, and existing intraocular pressure reduction treatment still cannot completely prevent neurodegenerative progress. Experiments prove that the miR-27a-3p inhibitor can be combined with 3 'UTR of PLK2 in a targeted mode, expression of the PLK2 is up-regulated, a PI3K / AKT signal channel is activated, and therefore RGC apoptosis is inhibited. A new glaucoma treatment strategy is provided, and the miR-27a-3p inhibitor can serve as an effective medicine to be used for improving glaucoma symptoms, protecting RGC and delaying disease progression and has good application prospects.

The invention belongs to the technical field of intelligent medical treatment, and relates to a biaxial intelligent intraocular pressure dynamic measurement and health management method, which comprises the following steps: preliminarily screened fused physiological signals comprise continuous intraocular pressure data and pressure state data in a synchronous time period; identifying the preliminarily screened fused physiological signals to generate an intraocular pressure event portrait representing risk causes; the intraocular pressure event portrait is analyzed to generate a comprehensive intervention file containing a coping strategy, and the comprehensive intervention file contains differentiated behavior intervention instructions; executing the comprehensive intervention file to generate real-time feedback data of intervention aftereffect; evaluating real-time feedback data of the intervention aftereffect to generate a hierarchical drug release decision; a hierarchical drug release decision is performed to generate a scaled drug release control signal. The problems that medicine waste and side effect accumulation are possibly caused when intraocular pressure is normal due to the fact that timed medicine dropping cannot be accurately matched with the actual intraocular pressure peak are solved.

The invention discloses an application of an exosome let-7b-5p from circulating blood plasma as a diagnostic marker of normal intraocular pressure glaucoma. The invention discloses application of a reagent for detecting the expression quantity of hsalet-7b-5p in preparation of a reagent for auxiliary diagnosis of normal intraocular pressure type glaucoma. Through high-throughput sequencing and quantitative PCR analysis in nearly 225 patients, it is found that let-7b-5p in plasma-derived exosomes can effectively distinguish normal intraocular pressure type glaucoma patients from normal people and cataract or other common ophthalmic disease patients, the sensitivity is high, the specificity is good and is far higher than that of an existing detection method, and the kit is suitable for clinical application. And the diagnosis performance is extremely excellent. An important basis is provided for diagnosis of the normal intraocular pressure type glaucoma, and the method has significance for prevention and treatment of the normal intraocular pressure type glaucoma in China.